Abstract
Pancreatic cancer has a extremely high malignancy, and simple surgical resection can not significantly improve the long-term survival rate of patients. Neoadjuvant therapy is the preoperative chemotherapy or combined chemo-radiotherapy, which is used for downstaging tumors, eliminating subclinical metastases, transforming unresectable into resectable tumors, and improving the R0 resection rate of pancreatic cancer, thus ultimately improving the efficacy of pancreatic cancer. At present, neoadjuvant therapy has gradually become the mainstream treatment for locally advanced and borderline resectable pancreatic cancer. New adjuvant therapy for resectable pancreatic cancer has been supported by some high-quality clinical research data, which will become a hot topic in clinical research. The author believes that there will be more clinical research data to help individualized neoadjuvant treatment selection, accurate efficacy evaluation and prognosis judgement, and ultimately improve the efficacy of patients with pancreatic cancer. Key words: Pancreatic neoplasms; Pancreatic cancer; Resectable pancreatic cancer; Borderline resectable pancreatic cancer; Unresectable pancreatic cancer; Neoadjuvant therapy
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
